Send to

Choose Destination
Pak J Pharm Sci. 2018 Jul;31(4):1279-1284.

Oral administration of honokiol attenuates airway inflammation in asthmatic mouse model.

Author information

Division of Respiratory diseases, People's hospital of Sichuan province, Chengdu, Sichuan, People's Republic of China.
Open laboratory, West China Second university hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China.


Allergic asthma is a disease that pathologically characterized by eosinophilia infiltration, airway inflammation and hyper responsiveness. In this study, we evaluated the anti-inflammatory and anti-allergy possibilities of honokiol, a bi-phenolic compound obtained from species of the genus Magnolia, which has long been involved in traditional Chinese prescriptions for asthma-related lung diseases, in an ovalbumin-induced mouse model of allergic asthma. We found honokiol significantly inhibited the eosinophilia infiltration, reduced the airway inflammation and suppressed the production of inflammatory cytokines) as well as the IgE in serum. Moreover, MMP-9 and? (IL-4 and IFN- NF-κB were found to be involved in the honokiol induced biological process. These results suggested that honokiol may be a possible candidate in the treatment of lung asthma related diseases.

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center